Clinical trials: Pancreatic Cancer Stage I
Pancreatic Cancer
Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00010062
- Testing
- fluorouracil, radiation therapy
- Where
- 30 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer, Esophageal Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00025532
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Sponsor
- University of California, San Francisco
Pancreatic Cancer
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low.
- Trial name
- NCT03989310
- Testing
- Manganese Chloride, nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Pancreatic Cancer
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
- Trial name
- NCT00398086
- Testing
- Gemcitabine, Albumin-bound paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Celgene
Pancreatic Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Gemcitabine may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00010166
- Testing
- gemcitabine hydrochloride, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
- Trial name
- NCT00614653
- Testing
- Bevacizumab, Erlotinib, Capecitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Neoplasms, Pancreatic Cancer
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
- Trial name
- NCT01161186
- Testing
- nab-paclitaxel, gemcitabine, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Francisco
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Pancreatic Cancer
Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer
The primary purpose of this study is to determine the best dosage of Capecitabine and Tarceva combination in the setting of radiation and to assess treatment effectiveness, progression-free survival and overall survival.
- Trial name
- NCT00565487
- Testing
- Capecitabine, Tarceva
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Milton S. Hershey Medical Center
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer
Treatment, Prospective, Assignment, Open Label, Single-center, Non-randomized Study An exploratory clinical trial of comparison of Nab-Paclitaxel combined with Gemcitabine and Gemcitabine combined with Tegafur for adjuvant…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT04216758
- Testing
- nab-paclitaxel, Gemcitabine, tegafur
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Pancreatic Cancer
PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00467116
- Testing
- cetuximab, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma
ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer
This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it…
- Conditions
- Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT01825603
- Testing
- ADH-1, Cisplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Nebraska
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Pancreas Cancer, CAR-T Cell Therapy
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
The second generation of mesothelin targeted CAR-T cells that secret a fusion protein of IL21 and scfv against PD1 have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies.
- Conditions
- Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult
- Trial name
- NCT05779917
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Pancreatic Cancer
Study of CellCept for Advanced Pancreatic Cancer
Mycophenolate Mofetil (CellCept) is an FDA approved, well tolerated, oral medication used to prevent the body's immune system from attacking transplanted organs.
- Trial name
- NCT00997958
- Testing
- Mycophenolate mofetil
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Pancreatic Neoplasms
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine.
- Trial name
- NCT00732082
- Testing
- Gemcitabine, LAG-3
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT07595172
- Testing
- NALIRIFOX+Adebrelimab, PULSAR
- Where
- China
- Volunteers
- 55 people
- Sponsor
- West China Hospital
Pancreatic Cancer
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer.
- Trial name
- NCT00783172
- Testing
- Gemcitabine, Opioid Growth Factor (OGF)
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Pancreatic Cancer
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.
- Trial name
- NCT00209677
- Testing
- Gemcitabine, S-1
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group